|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 7 (October 1), 1999:
pp. 2252-2258
The Effect of a Metalloproteinase Inhibitor (GI5402) on Tumor Necrosis
Factor- (TNF- ) and TNF- Receptors During Human Endotoxemia
Pascale E.P. Dekkers,
Fanny N. Lauw,
Tessa ten Hove,
Anje A. te
Velde,
Philip Lumley,
David Becherer,
Sander J.H. van Deventer, and
Tom van der Poll
From the Academic Medical Center, University of Amsterdam, Laboratory
of Experimental Internal Medicine, Amsterdam, the Netherlands;
Department of Clinical Pharmacology, Glaxo Wellcome, Greenford, UK; and
the Department of Biochemistry, Glaxo Wellcome, Research Triangle Park,
NC.
Tumor necrosis factor- (TNF- ) is released from the cell
surface by cleavage of pro-TNF- by metalloproteinases (MPs). In cell cultures, inhibition of MPs has been found not only to reduce the
release of TNF- , but also to enhance the surface expression of
TNF- and TNF- receptors, which might lead to a proinflammatory effect. To determine the effect of MP inhibition during inflammation in
humans, 7 healthy subjects were studied after intravenous injection of
lipopolysaccharide (LPS; 4 ng/kg) preceded ( 20
minutes) by an oral dose of the MP inhibitor GI5402 (100 mg) or
matching placebo. GI5402 strongly reduced LPS-induced TNF- release
(P < .001), but did not influence the increase in
monocyte-bound TNF- . In addition, GI5402 attenuated the rise in
plasma-soluble TNF- receptors types I and II after LPS injection
(both P < .001), but did not change the LPS-induced decreases
in granulocyte and monocyte TNF- receptor expression. These data
suggest that MP inhibitors may be useful as a treatment modality in
diseases in which excessive production of TNF- is considered to play
an important role. Furthermore, unlike in vitro, no evidence has been
found in vivo with MP inhibition for a potential proinflammatory effect
due to increases in membrane-bound TNF- and TNF- receptor number.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. O. Badellino, M. L. Wolfe, M. P. Reilly, and D. J. Rader
Endothelial Lipase Is Increased In Vivo by Inflammation in Humans
Circulation,
February 5, 2008;
117(5):
678 - 685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bahador and A. S. Cross
Review: From therapy to experimental model: a hundred years of endotoxin administration to human subjects
Innate Immunity,
October 1, 2007;
13(5):
251 - 279.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Qian, S. A. Bai, B. Brogdon, J.-T. Wu, R.-Q. Liu, M. B. Covington, K. Vaddi, R. C. Newton, M. J. Fossler, C. E. Garner, et al.
Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor {alpha}-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans
Drug Metab. Dispos.,
October 1, 2007;
35(10):
1916 - 1925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. P. J. Alwayn, C. Andersson, S. Lee, D. A. Arsenault, B. R. Bistrian, K. M. Gura, V. Nose, B. Zauscher, M. Moses, and M. Puder
Inhibition of matrix metalloproteinases increases PPAR-{alpha} and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model
Am J Physiol Gastrointest Liver Physiol,
December 1, 2006;
291(6):
G1011 - G1019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Marsik, B. Jilma, C. Joukhadar, C. Mannhalter, O. Wagner, and G. Endler
The Toll-Like Receptor 4 Asp299Gly and Thr399Ile Polymorphisms Influence the Late Inflammatory Response in Human Endotoxemia
Clin. Chem.,
November 1, 2005;
51(11):
2178 - 2180.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Guler, M. L. Olleros, D. Vesin, R. Parapanov, and I. Garcia
Differential Effects of Total and Partial Neutralization of Tumor Necrosis Factor on Cell-Mediated Immunity to Mycobacterium bovis BCG Infection
Infect. Immun.,
June 1, 2005;
73(6):
3668 - 3676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Satoh, J. Iwasaka, M. Nakamura, T. Akatsu, Y. Shimoda, and K. Hiramori
Increased expression of tumor necrosis factor-{alpha} converting enzyme and tumor necrosis factor-{alpha} in peripheral blood mononuclear cells in patients with advanced congestive heart failure
Eur J Heart Fail,
December 1, 2004;
6(7):
869 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, J. Xu, J. Levin, M. Hegen, G. Li, H. Robertshaw, F. Brennan, T. Cummons, D. Clarke, N. Vansell, et al.
J. Pharmacol. Exp. Ther.,
April 1, 2004;
309(1):
348 - 355.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S J H van Deventer
A place for TACE
Gut,
July 1, 2002;
51(1):
5 - 6.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Brynskov, P Foegh, G Pedersen, C Ellervik, T Kirkegaard, A Bingham, and T Saermark
Tumour necrosis factor {alpha} converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
Gut,
July 1, 2002;
51(1):
37 - 43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Beck, G. Bottomley, D. Bradshaw, M. Brewster, M. Broadhurst, R. Devos, C. Hill, W. Johnson, H.-J. Kim, S. Kirtland, et al.
(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a Selective and Orally Active Inhibitor of Tumor Necrosis Factor-alpha Convertase
J. Pharmacol. Exp. Ther.,
July 1, 2002;
302(1):
390 - 396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S J H van Deventer
Small therapeutic molecules for the treatment of inflammatory bowel disease
Gut,
May 1, 2002;
50(90003):
iii47 - 53.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Olleros, R. Guler, N. Corazza, D. Vesin, H.-P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia
Transmembrane TNF Induces an Efficient Cell-Mediated Immunity and Resistance to Mycobacterium bovis Bacillus Calmette-Guerin Infection in the Absence of Secreted TNF and Lymphotoxin-{alpha}
J. Immunol.,
April 1, 2002;
168(7):
3394 - 3401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Conway, R. C. Andrews, B. Beaudet, D. M. Bickett, V. Boncek, T. A. Brodie, R. L. Clark, R. C. Crumrine, M. A. Leenitzer, D. L. McDougald, et al.
Inhibition of Tumor Necrosis Factor-alpha (TNF-alpha ) Production and Arthritis in the Rat by GW3333, a Dual Inhibitor of TNF-alpha -Converting Enzyme and Matrix Metalloproteinases
J. Pharmacol. Exp. Ther.,
September 1, 2001;
298(3):
900 - 908.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. E. P. Dekkers, T. ten Hove, F. N. Lauw, H. R. Koene, P. Lumley, S. J. H. van Deventer, and T. van der Poll
The Metalloproteinase Inhibitor GI5402 Inhibits Endotoxin-Induced Soluble CD27 and CD16 Release in Healthy Humans
Infect. Immun.,
May 1, 2000;
68(5):
3036 - 3039.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|